Diabetes mellitus, metformin, and the risk of MPN.
作者信息
Krecak Ivan, Klobucar Sanja, Budimir Josipa, Skelin Marko, Lucijanic Marko
机构信息
Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia.
Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
出版信息
Blood Adv. 2024 Nov 26;8(22):5929-5931. doi: 10.1182/bloodadvances.2024013772.
Abstract
摘要
相似文献
1
Diabetes mellitus, metformin, and the risk of MPN.糖尿病、二甲双胍与骨髓增殖性肿瘤风险
Blood Adv. 2024 Nov 26;8(22):5929-5931. doi: 10.1182/bloodadvances.2024013772.
2
Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study.二甲双胍的使用与骨髓增生性肿瘤风险：一项丹麦基于人群的病例对照研究。
Blood Adv. 2024 Aug 27;8(16):4478-4485. doi: 10.1182/bloodadvances.2023012266.
3
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature.糖尿病与胃癌的关系及二甲双胍的潜在获益：文献综述。
Biomolecules. 2021 Jul 13;11(7):1022. doi: 10.3390/biom11071022.
4
Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital.二甲双胍在糖尿病合并结核病患者中作为潜在的保护性治疗：单教学医院的回顾性队列研究。
J Diabetes Investig. 2021 Sep;12(9):1603-1609. doi: 10.1111/jdi.13523. Epub 2021 Mar 3.
5
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.二甲双胍和达格列净单独和联合治疗超重女性妊娠期糖尿病的随机试验。
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100139. doi: 10.1016/j.ajogmf.2020.100139. Epub 2020 May 16.
6
Metformin in patients with type 2 diabetes mellitus and heart failure: a review.二甲双胍在 2 型糖尿病合并心力衰竭患者中的应用：综述。
Endokrynol Pol. 2021;72(2):163-170. doi: 10.5603/EP.a2021.0033.
7
Metformin decreases the risk of sudden sensorineural hearing loss in patients with diabetes mellitus: A 14-year follow-up study.二甲双胍可降低糖尿病患者突发感音神经性聋的风险：一项为期 14 年的随访研究。
Diab Vasc Dis Res. 2019 Jul;16(4):324-327. doi: 10.1177/1479164119826292. Epub 2019 Feb 2.
8
Diabetes mellitus and metformin in hepatocellular carcinoma.糖尿病与二甲双胍在肝细胞癌中的作用
World J Gastroenterol. 2016 Jul 21;22(27):6100-13. doi: 10.3748/wjg.v22.i27.6100.
9
Quantitative Proteome Analysis Reveals Increased Content of Basement Membrane Proteins in Arteries From Patients With Type 2 Diabetes Mellitus and Lower Levels Among Metformin Users.定量蛋白质组分析揭示2型糖尿病患者动脉中基底膜蛋白含量增加，而二甲双胍使用者含量较低。
Circ Cardiovasc Genet. 2015 Oct;8(5):727-35. doi: 10.1161/CIRCGENETICS.115.001165. Epub 2015 Sep 14.
10
Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus.二甲双胍对 2 型糖尿病急性缺血性脑卒中患者结局的影响。
J Stroke Cerebrovasc Dis. 2022 Sep;31(9):106648. doi: 10.1016/j.jstrokecerebrovasdis.2022.106648. Epub 2022 Jul 18.
引用本文的文献
1
The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes.在无糖尿病登记标记的患者中使用二甲双胍与骨髓增殖性肿瘤风险
Blood Adv. 2024 Nov 26;8(22):5932-5934. doi: 10.1182/bloodadvances.2024014173.
2
Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications.真性红细胞增多症中的全身炎症指数及其预后意义。
J Clin Med. 2024 Jul 30;13(15):4459. doi: 10.3390/jcm13154459.
本文引用的文献
1
High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera.真性红细胞增多症中，高红细胞量和高血浆容量与血栓形成风险独立相关。
Leuk Lymphoma. 2024 Nov;65(11):1724-1728. doi: 10.1080/10428194.2024.2368639. Epub 2024 Jun 20.
2
Survival analysis of diabetes cardiovascular outcome trials using reconstructed Kaplan-Meier curves.使用重构的Kaplan-Meier曲线对糖尿病心血管结局试验进行生存分析。
Eur J Intern Med. 2024 Oct;128:153-155. doi: 10.1016/j.ejim.2024.05.026. Epub 2024 May 25.
3
Being John Plasma Volumovich, pecularities of plasma volume estimation in patients with polycythemia vera.身为约翰·血浆容量维奇，真性红细胞增多症患者血浆容量估计的特点。
Thromb Res. 2024 Jul;239:109039. doi: 10.1016/j.thromres.2024.109039. Epub 2024 May 22.
4
Metformin use and risk of myeloproliferative neoplasms: a Danish population-based case-control study.二甲双胍的使用与骨髓增生性肿瘤风险：一项丹麦基于人群的病例对照研究。
Blood Adv. 2024 Aug 27;8(16):4478-4485. doi: 10.1182/bloodadvances.2023012266.
5
The impact of statin use on disease-related symptoms in patients with chronic myeloproliferative neoplasms.他汀类药物使用对慢性骨髓增殖性肿瘤患者疾病相关症状的影响。
Ann Hematol. 2024 May;103(5):1783-1785. doi: 10.1007/s00277-024-05693-0. Epub 2024 Mar 13.
6
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症中的糖化血红蛋白（HbA1c）与血栓形成风险
Leuk Lymphoma. 2024 May;65(5):688-691. doi: 10.1080/10428194.2024.2304619. Epub 2024 Jan 22.
7
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.慢性骨髓增殖性肿瘤患者心血管危险因素的再评估。
Clin Adv Hematol Oncol. 2023 Oct;21(10):541-548.
8
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.他汀类药物的使用与老年原发性血小板增多症和特发性骨髓纤维化患者的生存及血栓发生率。
Cancer Med. 2023 Sep;12(18):18889-18900. doi: 10.1002/cam4.6528. Epub 2023 Sep 13.
9
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.BCR::ABL1 阴性慢性骨髓增殖性肿瘤患者心血管风险因素管理的优化：现有知识和观点。
Ann Hematol. 2024 May;103(5):1513-1523. doi: 10.1007/s00277-023-05426-9. Epub 2023 Sep 4.
10
Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: Impact on hemoglobin/hematocrit levels and outcomes among 11 consecutive patients.钠-葡萄糖协同转运蛋白2抑制剂治疗原发性血小板增多症：对11例连续患者血红蛋白/血细胞比容水平及预后的影响
Am J Hematol. 2023 Nov;98(11):E298-E300. doi: 10.1002/ajh.27048. Epub 2023 Aug 8.
Zotero 插件